With a focus on community-specific risks, this postdoc reveals the molecular roots of pancreatic cancer to guide personalized care.
Q | Write a brief introduction to yourself including the lab you work in and your research background.
I introduce myself as Zahid Rafiq. Currently, I am a postdoctoral fellow and a cancer pharmacologist serving for the School of Pharmacy here at the University of Texas, El Paso (UTEP). I am engaged in advanced pancreatic cancer research under a career transition program funded by the Cancer Prevention and Research Institute of Texas (CPRIT-TREC). My current research focuses on investigating mechanisms and risk factors specific to the Hispanic population that lead to tumorigenesis at the molecular and cellular levels, aiming to develop personalized anticancer strategies.
Q | How did you first get interested in science and/or your field of research?
I have worked in world class institutes including MD Anderson Cancer Center (MDACC), where I worked as a postdoctoral fellow. Here, my research focused on developing combined therapeutic strategies using low-dose radiotherapy (LD-XRT) and adoptively transferred CAR-T cells to ensure durable responses that control metastatic disease. In addition to this, I also finished an immunometabolism project in collaboration with Takeda Pharma to find out the time and dose dependent effects of radiation on the metabolism of T cells. This project complemented my career goals and provided me with new knowledge to understand the role of radiation, immune responses, and cell therapy. In summary, I have the expertise, training, leadership, and motivation necessary to execute the proposed research project successfully. In addition to research endeavors, I am an active member of leading scientific organizations, including the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
Continue reading below…
Like this story? Sign up for FREE Cancer updates:
Q | Tell us about your favorite research project you’re working on.
My favorite research project has been developing combined therapeutic strategies using low-dose radiotherapy (LD-XRT) and adoptively transferred CAR-T cells to ensure durable responses that control metastatic disease.
Q | What do you find most exciting about your research project?
The most exciting part of my scientific journey has been doing interesting projects and conferences.
Q | If you could be a laboratory instrument, which one would you be and why?
If I could be a laboratory instrument, I would like to be a digital scanner and reader as it is fast and reliable.
Are you a researcher who would like to be featured in the “Postdoc Portraits” series? Send in your application here.
